Revenue from Contracts with Customers

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Note 5 - Revenue from Contracts with Customers

Disaggregated Revenue

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

	Years Ended December,
	2020		2019
Product sales	$	2,704,364	$	2,168,179
Laboratory services		167,736		5,435
Collaboration revenue		1,342,341		1,325,000
Total revenue	$	4,214,441	$	3,498,614

Revenues by geography are as follows:

	Years Ended December,
	2020		2019
Domestic	$	1,917,367	$	3,322,615
International		2,297,074		175,999
Total revenue	$	4,214,441	$	3,498,614

Deferred revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2019	$	9,808
Acquired deferrals from Curetis		829,275
Revenue recognized in the current period from the amounts in the beginning balance		—
Revenue recognized in the current period from the amounts acquired from Curetis		(870,114	)
Effect of foreign exchange rates		40,839
Balance at December 31, 2020	$	9,808

Contract assets

The Company had approximately $18,000 of contract assets as of December 31, 2020, which are generated when contractual billing schedules differ from revenue recognition timing. The Company had no contract assets as of December 31, 2019. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

Unsatisfied performance obligations

The Company had no unsatisfied performance obligations related to its contracts with customers at December 31, 2020 and 2019.